Print

HVTN 704 AMP

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

Trial Details:

IIb Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) March 01, 2016
VRC-HIVMAB060-00-AB VRC01 Antibody
VRC-HIVMAB060-00-AB Passive Immunization
USA, Peru, Brazil 2700
NCT02716675
https://clinicaltrials.gov/ct2/show/NCT02716675